Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

VYGR Long-term Debt

Borrowings due after more than one year.

Voyager Therapeutics, Inc.NASDAQ: VYGR

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt remains negative

Q1 FY2026 long-term debt was $0, compared with $0 a year earlier.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Long-term Debt vs competitors

How VYGR compares with its peers on the latest reported figures

  • VYGR's Mar 2026 long-term debt of $0 is the 5th highest of the 11 companies compared; the peer median is $0.
  • Long-term debt amounts to 0.0% of total assets for VYGR, versus a peer median of 0.0%.
VYGR Competitors Peer median
Long-term Debt for VYGR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$98.62M -22.2%+329.1%31.3%
HUMAHumacyte, Inc.Mar 2026$35.87M -44.5%+20.3%32.4%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$19.68M +31.2%—8.0%
ACHVAchieve Life Sciences, Inc.Mar 2026$9.32M +7.7%—28.2%
VYGRVoyager Therapeutics, Inc.Mar 2026$0 ——0.0%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
SGMTSagimet Biosciences Inc.Mar 2026$0 ——0.0%
ALLOAllogene Therapeutics, Inc.Mar 2026$0 ——0.0%
VNDAVanda Pharmaceuticals Inc.Mar 2026$0 ——0.0%
TRDAEntrada Therapeutics, Inc.Mar 2026$0 ——0.0%
PYXSPyxis Oncology, Inc.Mar 2026$0 ——0.0%
Peer median (excluding VYGR) $0-7.2%+174.7%0.0%

Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents117.43M98.96M68.8M71.37M65.3M
Short-term Investments15.11M19.89M162.07M195.32M131.15M
Net Receivables748K639K84.46M4.49M1.76M
Inventory00000
Other Current Assets1.7M4.23M2.63M2.87M4.48M
Total Current Assets136.7M124.5M319.68M276.81M202.69M
Property, Plant & Equipment (Net)55.38M33.34M30M47.66M41.61M
Goodwill00000
Intangible Assets00000
Long-term Investments00065.7M0
Tax Assets00000
Other Non-current Assets1.78M1.52M1.59M2.87M7.98M
Total Non-current Assets57.16M34.86M31.6M116.24M49.59M
Total Assets193.86M159.36M351.28M393.05M252.28M
Account Payables574K2.57M1.6M4M5.01M
Short-term Debt00000
Tax Payables00000
Deferred Revenue33.89M59.38M42.88M24.39M1.59M
Other Current Liabilities5.02M4.56M6.61M6.75M9.09M
Total Current Liabilities50.98M72.59M64.51M49.79M26.54M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)8.21M6.45M32.36M6M0
Other Non-current Liabilities1M1M1M1M1M
Total Non-current Liabilities47.82M27.75M50.45M43.5M29.66M
Total Liabilities98.8M100.34M114.96M93.29M56.2M
Common Stock38K38K44K55K59K
Retained Earnings(347.1M)(393.51M)(261.18M)(326.18M)(445.91M)
Accumulated OCI(138K)(219K)(48K)(407K)32K
Other Stockholders Equity00000
Minority Interest00000
Total Equity95.06M59.02M236.32M299.76M196.08M
Total Debt44.18M23.13M20.29M43.73M36.5M
Net Debt(73.25M)(75.83M)(48.51M)(27.64M)(28.8M)

Voyager Therapeutics, Inc.

NASDAQ:VYGR

Intrinsic Alpha fair value

Locked

Current Price

$1.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.